Conclusions 1. Administration of RE is safe 2. Cohesive multidisciplinary working is critical 3. There is a strong evidence base for the efficacy of RE in delaying TTP and improving median survival in first, second and subsequent lines of therapy for mCRC and for down-sizing inoperable mets to resection or ablation 4. Dosing regimes exist for combination of RE with 5-fluorouracil, oxaliplatin or irinotecan |